Review
Copyright ©The Author(s) 2023.
World J Diabetes. Jun 15, 2023; 14(6): 741-757
Published online Jun 15, 2023. doi: 10.4239/wjd.v14.i6.741
Table 2 Available therapeutic medications for management of diabetic neuropathy
Management strategy
Therapeutic approach
Description
Contraindications/issues
PharmacologicalAnti-convulsants: Gabapentin; pregabalinFirst line medication for painful DN[4,51]; gold standard for pain management[50,51]Reports on misuse and increased death rate in patients[54]
SSRI and SNRIs: Duloxetine; venlafaxineFirst- and second-line therapy for painful DN[56,57]Low evidence on venlafaxine effectiveness for painful DN treatment[58]
TCAs: Amitriptyline; desapramineFirst and second-line therapy for painful DNAssociated with constipation, dry mouth, sleep disturbance, sexual dysfunction, somnolence, headaches, arrhythmias, constipation, sleep disturbances, and postural hypotension[4,63]
Opioids: Tramadol; trapentadolOpted as acute salvage treatment or as a part of drug combination for painful DN treatmentStrong opioids are frequently associated with therapeutic abuse and misuse[68]; use of tramadol is more preferred due to reduced risk of abuse or misuse[68]
Sympathetic blocking agents (α-adrenergic antagonists): Clonidine; regitine; phenoxybenzamineOne of the opted therapies for complex regional pain syndrome treatment[72]Limited evidence in RCT testing the drug’s efficacy in painful DN patients; efficiency of clonidine depends on relative functionality of nociceptors in painful DN patients, however no statistical significance is achieved although the trends of efficacy is shown[70]
Non-pharmacologicalSympathetic nerves blockade: Lumbar sympathetic nerves blockade; combined strategies of lumbar sympathetic pulsed radiofrequency and continuous epidural infusion; combined treatment of continuous sympathetic block and neurolysis with alcoholRecommended for severe painful DN patients who failed to any pharmacological treatments Patients demonstrated improved life expectancy, greater DN symptom improvement, satisfactory safety, rapid recovery, and rapid relief of pain[73-76]; associated with several limitations of additional diagnostic tools, small size population, short period of follow-up, and issue regarding combined treatment duration[75,76]
CapsaicinRecommended for patients with intolerable oral therapeutic consumption[4]Low to moderate level of evidence for topical capsaicin efficacy[82,83]; associated with small nerve fibers injury and disturbed nociceptive signaling[84]
Neuromodulation devices: FREMS; SCS, NMES; TENSStudies on their efficacy in painful DN is still on-goingNot yet approved for clinical guidelines for painful DN treatment due to very low evidence of efficacy[4,85,86]
Nutraceuticals: ALA; ALC; vitamin B12ALA improves numbness and paraesthesia with reduced side effects[89]; vitamin B12 is recommended to T2DM patients with metformin prescription[90]There is a lack of standardization in quality and manufacturing of nutraceuticals[91,92]; low safety level due to less evidence of high-quality studies[87,93]